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Tyrosinase inhibition studies are needed due to the medicinal applications such as hyperpigmentation. For probing eﬀective
inhibitors oftyrosinase, a combinationof computationalprediction and enzymaticassayvia kinetics was important. We predicted
the 3D structure of tyrosinase, used a docking algorithm to simulate binding between tyrosinase and phthalic acid (PA), and
studied thereversible inhibitionoftyrosinaseby PA.PAinhibited tyrosinaseina mixed-type mannerwith a Ki = 65.84±1.10mM.
Measurements of intrinsic and ANS-binding ﬂuorescences showed that PA induced changes in the active site structure via indirect
binding. Simulation was successful (binding energies for Dock6.3 =− 27.22 and AutoDock4.2 =− 0.97kcal/mol),suggesting that
PA interacts with LEU73 residue that is predicted commonly by both programs. The present study suggested that the strategy of
predicting tyrosinase inhibition based on hydroxyl groups and orientation may prove useful for screening of potential tyrosinase
inhibitors.
1.Introduction
Melanogenesis isa complexmechanism formelanin pigment
production. Tyrosinase (monophenol, dihydroxyphenylala-
nine: oxygen oxidoreductase, EC 1.14.18.1) plays a central
role in melanin synthesis as a copper-binding metalloen-
zyme. It is ubiquitously distributed in organisms and has
multi catalytic functions such as the hydroxylation of
tyrosine to DOPA, the oxidation of DOPA to DOPAquinone,
and the oxidation of 5,6-dihydroxyindole [1–3]. Besides
the catalytic features, tyrosinase is distinctive from the
other enzymes as it displays various inhibition patterns.
Several previous studies suggest [4–6] that tyrosinase can
induce neurotoxicity by activating apoptotic stress signaling
pathways and is directly associated with a neurotoxic over-
production of cellular dopamine. It implies that tyrosinase
gene expression results in oxidative metabolites and reactive
oxygen species at the cellular level which are known to have
cytotoxic eﬀects.
Tyrosinase is directly related with severe skin diseases
such as type 1 albinism (http://albinismdb.med.umn.edu/)
andmelanoma [7–9].Mutationsoftyrosinase genecancause
severe skin disease such as oculocutaneous albinism (OCA).
Three types of OCA—tyrosinase-negative, yellow-mutant,
and temperature-sensitive OCA—havebeenwell known [10,
11], and new subtypes of albinism have been reported [12].
Tyrosinase is also involved in the skin hyperpigmentation
and in this regard, tyrosinase inhibition study is directly
associated with the treatment of melanin overproduction
[13–15].
The tyrosinase mechanism is complex, in that this
enzyme can catalyze multiple reactions. The crystallographic
structure of tyrosinase has not been determined; thus, the
overall 3D structure and architecture of the active site are
not well understood regardless of several reports [16–18].
Studies of this enzyme mechanism must involve a variety of
computational methods and kinetics to derive the structure-
function relationships, for example, between substrates and
ligands of the enzyme.
In the current study we determined the mechanism of
tyrosinase inhibition by PA using computational simulation
and kinetic analysis. We hypothesized that the two hydroxyl
groups of PA may block L-DOPA oxidation by binding to
tyrosinase. Previous ﬁndings have shown the importance of2 Enzyme Research
hydroxyl groups in tyrosinase inhibition [19–22]i nt e r m so f
molecular position, number, and speciﬁc interactions with
the enzyme; these ﬁndings further support our hypothesis.
PA has two hydroxyl groups, thus implying that PA might
have an inhibitory eﬀect on tyrosinase. Direct use of PA
in medicinal or cosmetic applications is limited due to
the toxicity; however, eﬀective approaches derived from the
combination of computational simulation and enzymatic
kinetics as an example case are of interest for further
screening tyrosinase inhibitor candidates. The computa-
tional simulation suggested that PA could be a potent
inhibitor for tyrosinase where PA can directly interact with
someresidues locating near totheactivesite.Experimentally,
PA exerts a mixed type of inhibition on tyrosinase. Kinetic
parameters have consistently supported the result of docking
simulation, and measurements of ANS-binding ﬂuorescence
have revealed changes in the regional structure. A combina-
tion of inhibition kinetics and computational modeling may
facilitate testing of potential tyrosinase inhibitors, such as PA
and prediction of the inhibitory mechanisms.
2.Materialsand Methods
2.1.Materials. Tyrosinase (M.W. 128kDa),L-DOPA,and PA
were purchased from Sigma-Aldrich (Seoul, Korea). When
L-DOPAwas used as a substrate inour experiments, the pur-
chased tyrosinase had aKm of0.30±0.02mM(Vmax = 0.13±
0.05mmol·min−1) according to a Lineweaver-Burk plot.
All kinetic reactions and measurements in this study were
performed in 50mM sodium phosphate buﬀer (pH 6.9).
2.2. Tyrosinase Assay and Kinetic Analysis for the Mixed-
Type Inhibition. A spectrophotometric tyrosinase assay was
performed as previously described [23, 24]. To begin the
assay, a 10-μL sample of enzyme solution was added to 1mL
of reaction mix. Tyrosinase activity (v) was recorded as the
change in absorbance per min at 492nm using a Perkin
Elmer Lambda Bio U/V spectrophotometer. To describe
the mixed-type inhibition mechanism, the Lineweaver-Burk
equation in double reciprocal form can be written as
1
v
=
Km
Vmax

1+
[I]
Ki

1
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1
Vmax
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αKi

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Secondary plots can be constructed from
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Then, the α, Ki, Km,a n dVmax values can be derived
from the above equations. The secondary replot of Slope
or Y-intercept versus [I] is linearly ﬁtted, assuming a single
inhibition site or a single class of inhibition site, as shown in
Scheme 1.
2.3. Intrinsic and ANS-Binding Fluorescence Measurements.
Fluorescence emission spectra were measured with a Jasco
E+S ES E + P
II
Ki αKi
++
Km
EI + S EIS EI + P
αKm
Scheme 1
FP750 spectroﬂuorometer using a cuvette with a 1-cm path
length. Tryptophan ﬂuorescence was measured following
excitation at 280nm, and the emission wavelength ranged
between 300 and 410nm. Changes in the ANS-binding ﬂu-
orescence of tyrosinase were measured following excitation
at 390nm, and the emission wavelength ranged from 400
to 520nm. The tyrosinase was labeled with 40μMA N Sf o r
30min prior to measurements.
2.4. Determination of the Binding Constant and the Number
of Binding Sites. According to a previous report [25],
when small molecules are bound to equivalent sites on a
macromolecule, the equilibrium between free and bound
molecules is given by the following equation:
F0
F0 −F
=
1
n
+
1
K
1
[Q]
,( 4 )
where F0 and F are the relative steady-state ﬂuorescence
intensities in the absence and presence of quencher, respec-
tively, and [Q] is the quencher (PA) concentration. The
values for the binding constant (K) and number of binding
sites (n) can be derived from the intercept and slope of a plot
based on (4).
2.5. Homology Modeling of Tyrosinase and Docking Simula-
tions. The 3D structure of tyrosinase from Agaricus bisporus
was modeled using the SWISS-MODEL[26] to assemble 556
amino acids (Protein CAA11562) selected with a homology-
modelingprotocol.Thismethoddiﬀersfromthosedescribed
in previous reports [17, 18]. We retrieved the known
homologues of tyrosinase (average, 23% sequence identity),
as well as partial tyrosinase homologues, from the Protein
Data Bank (PDB) (http://www.pdb.org/)a n di d e n t i ﬁ e da
PDB entry (2zmx chain A) to provide a suitable structural
template. Based on the sequencealignment, the 3D structure
of tyrosinase was constructed with a high level of conﬁdence
(ﬁnal total energy, 38297.020KJ/mol).
Among the many tools available for protein-ligand
docking, Dock6.3 and Autodock4.2 programs were applied
becauseoftheirautomatedcapability[27].Theprogramuses
a set of predeﬁned 3D grids of the target protein with a
systematic search technique [28]. The original structure of
PA was derived from the PubChem database (Compound
ID: 1017, http://pubchem.ncbi.nlm.nih.gov/). To prepare
for the docking procedure, the following steps were taken:
(1) conversion of 2D structures to 3D structures; (2)Enzyme Research 3
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Figure 1: Inhibitory eﬀect of PA on tyrosinase. Data are presented as the means (n = 3). Tyrosinase was incubated with PA at various
concentrations for 3h at 25◦C and then added to the assay system at the corresponding PA concentrations (a) or in the absence of PA. (b)
The ﬁnal concentrations of L-DOPA and tyrosinase were 2 mM and 2.0μg/mL, respectively.
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Figure 2: Plots of v versus [E]. The v value indicates the change
in absorbance at 492nm per minute at PA concentrations of 0,
100, 200, and 400mM (labels 1 to 4, resp.). The ﬁnal L-DOPA
concentration was 2mM.
calculation of charges; (3) addition of hydrogen atoms;
(4) location of pockets. For these steps, we used OpenEye
(http://www.eyesopen.com/).
3.Results
3.1. Eﬀect of PA on Tyrosinase Activity. We assayed tyrosinase
activity changes in the presence of PA. Tyrosinase activity
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Figure 3: Lineweaver-Burk plot. (a) The PA concentrations were
0( •), 50 (+), 100 (
￿), and 150mM (
￿). (b) The ﬁnal enzyme
concentration was 2.0μg/mL.
was conspicuously inactivated by PA in a dose-dependent
manner with an IC50 of 200 ± 5.0mM(n = 3), where PA
was present both in reaction and assay buﬀers (Figure 1(a)).
At less than 50mM PA, tyrosinase was slightly activated up
to 18% and, then, gradually inactivated by increasing PA
concentration (Figure 1(a)). When PA was removed from4 Enzyme Research
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Figure 4: Secondary replots. (a) Plot of Slope versus [PA]. All data were collected from Lineweaver-Burk plots. The replot was plotted based
on (2). (b) Plot of Y-intercept versus [PA]. The replot was plotted based on (3).
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Figure 5: Intrinsic ﬂuorescence changes by PA. Tyrosinase was
incubated with PA for 3h before measurements. Label 1 represents
the native state. Labels 2 through 9 indicate PA concentrations of
1.56, 3.125, 6.25, 12.5, 25, 50, 100, and 400mM, respectively.
the assay buﬀer, the residual activity was higher than 60%
even at 800mM PA (n = 3), implying that PA reversibly
binds to tyrosinase (Figure 1(b)). The phenomenon of slight
activation by PA at the low concentration was also observed
in Figure 1(b).
To conﬁrm the reversibility of PA-mediated inhibition,
plots of the remaining activity versus [E] were constructed
(Figure 2). The results showed straight lines passing through
the origin, indicating the PA-mediated reversible inhibition,
as predicted in results of Figure 1.
3.2. Lineweaver-Burk Plot Analysis of Tyrosinase Inhibition by
PA. We adapted Lineweaver-Burk plot analysis to elucidate
inhibition type and mechanism of PA on tyrosinase. The
results showed changes in both the apparent Vmax and the
Km, indicating that PA induced a mixed type of inhibition
(Figure 3). The secondary replots of Slope versus (PA) and
Y-intercept versus (PA) were linearly ﬁtted (Figures 4(a) and
4(b)), showing that PA has a single inhibition site or a single
class of inhibition site on tyrosinase. Using (1)–(3), the α-
value was calculated to be 9.05 ± 1.4 (n = 2), and the Ki was
65.84 ± 1.10mM (n = 2).
3.3. Eﬀect of PA on Tyrosinase Tertiary Structure Spectroﬂu-
orimetry Studies. Next, we measured the intrinsic ﬂuores-
cence changes of tyrosinase in the presence of PA. We
found that the intrinsic ﬂuorescence of tyrosinase is changed
signiﬁcantly accompanying a quenching eﬀect, which grad-
ually decreased with no signiﬁcant shift of the maximum
peak wavelength (Figure 5). At 400mM, PA completely
quenched the ﬂuorescence. For calculating binding aﬃnity,
a double reciprocal plot was evaluated according to (4)a s
shown in Figure 6. The result revealed a linear relationship,
we calculated the binding constant to be K = 0.068 ±
0.03mM−1, and the binding number was n = 1.01 ± 0.65
by using (4).
To compare the intrinsic ﬂuorescence result and further
to elucidate the changes in tyrosinase hydrophobicity due
to alterations of the active site shape by PA, the ANS-
bindingﬂuorescencechangesweremonitoredinthepresenceEnzyme Research 5
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Figure 6: Plot of maximum ﬂuorescence intensity versus [PA]. (a) Tyrosinase was incubated with various concentrations of PA (1.56 to
800mM). (b) Double reciprocal plot of F0/(F0 − F)v e r s u s[ Q]
−1. Data was treated according to (4). F0 maximum native ﬂuorescence
intensity; F maximum ﬂuorescence intensity of sample; Q quencher PA.
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Figure 7: Changes in ANS-binding ﬂuorescence of tyrosinase at
diﬀerent PA concentrations. ANS (40μM) was incubated with
tyrosinase for 30min to label the hydrophobic enzyme surfaces
prior to ﬂuorescence measurements. Data are presented as the
means (n = 2).
of PA (Figure 7). PA gradually increased the ANS-binding
ﬂuorescence of tyrosinase in a dose-dependent manner, an
indicationthatbindingtoinhibitorexposedthehydrophobic
surfaces withinthetyrosinase, which mightbemainly caused
f r o mt h ea c t i v es i t e .
ASP 240
THR 62
LEU 73 GLU 67
Figure 8: Computational docking simulation of binding between
tyrosinase and PA. The modeled 3D structure of tyrosinase using
SWISS-MODEL to assemble 556 amino acids selected with a
homology-modeling protocol. Two copper ions (balls) coordinated
with six histidines, as indicated the blue colors in the ﬁgure. The
p i n ks t i c ki sP Aa sd o c k e db yD o c k 6 . 3 .T h eg r e e ns t i c ki sP Aa s
docked by AutoDock4.2.
3.4. Computational Prediction of 3D Tyrosinase Structure and
Docking Simulation of PA Binding. Because the crystallo-
graphic structure of tyrosinase is not available, we selected
a template structure from the PDB (2zmxA) to simulate
the 3D structure of tyrosinase. In the predicted structure of
tyrosinase, a binding pocket is indicated with two coppers:
one is coordinated to HIS38, HIS54, and HIS63, and the
otheriscoordinatedtoHIS190,HIS194,andHIS216,respec-
tively (Figure 8).The dockingsimulation ofbinding between
PA and tyrosinase was successful in producing a signiﬁcant6 Enzyme Research
score (binding energy for Dock6.3was −27.22kcal/mol).We
searched for PA-binding residues within tyrosinase that were
close to each other and found the most important residues
at THR62, GLU67, LEU73, and ASP240 predicted from
Dock6.3. In the same way, AutoDock4.2 was also applied to
probe docking sites. As a result, PA-binding residues were
predicted as GLU67 and LEU73 with a relatively low score
(binding energy for AutoDock4.2 was −0.97kcal/mol). We
found that LEU73 has been commonly predicted from both
programs. The docking simulations provided informative
data for the PA as a tyrosinase inhibitor by identifying
binding residues near to active site pocket, which might
directly aﬀectthe L-DOPA substrate dockingand catalysis by
inducing regional structure changes.
4.Discussion
Previous studies have recognized an apparently potent
inhibitory eﬀect of compounds with hydroxyl groups on
tyrosinase [29–32]. In this context, we hypothesized that
PA could be a potent tyrosinase inhibitor due to the
structural aspect with two hydroxyl groups. To conﬁrm
our supposition, we simulated the docking between PA
and tyrosinase and conducted kinetic studies. As a result,
we found that PA was directly involved with tyrosinase
inhibition not via copper chelation but via mixed-type
manner. Experimentally, our kinetic studies consistently
conﬁrmed all results and the model described in Scheme 1.
The inhibitory mechanism of PA was partly similar to those
of copper chelators but still has diﬀerent aspect that PA
did not directly bind to coppers at the active site [33, 34].
Vmax value changes were predicted by docking simulation
that PA might not compete with L-DOPA for docking
because the binding sites are not located in the active site
pocket. However, the Km changes occurred in more complex
manner: L-DOPA did not directly compete with PA but the
L-DOPA accessibility for docking to coppers at the active site
couldbe aﬀectedbythePA-docking-inducedconformational
changes resulting in the tertiary shape of active site, and this
conformational change was conﬁrmed by monitoring the
hydrophobic surface changes of tyrosinase. This is due to
the reason that PA docking site is very near to the active site
where L-DOPA oxidation is occurred. Thus, the mixed-type
inhibition of tyrosinase by PA was observed.
Using computational simulations, we predicted that PA
bound directly with several residues (among them LEU73 is
the most signiﬁcant) of tyrosinase. This result is consistently
matched to the data in Figure 6 where the number of
binding site is calculated as approximately one. LEU73
residue is thought to be involved in the ﬁrst stage of PA
binding. Because the PA binding site is quite diﬀerent
to the L-DOPA binding site, it is not overlapped, but
relatively in close proximity, which may allow PA binding to
interact with the enzyme-substrate intermediate or another
step in catalysis (Vmax changes), and inducing detectable
hydrophobicchangesintheactivesite mayresultinretarding
L-DOPA accession (Km changes). Overall, the experimental
data ﬁt very well with data predicted by the simulations.
Taken together, our study provides new insight into
the role of several residues in tyrosinase and provides
useful information regarding the 3D structure of tyrosinase.
A combination of inhibition kinetics and computational
modeling may facilitate the testing of potential tyrosinase
inhibitorsandthepredictionoftheirinhibitorymechanisms.
The present study also suggested that the strategy of pre-
dicting tyrosinase inhibition based on hydroxyl groups and
orientation may prove useful for the screening of potential
tyrosinase inhibitors.
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